Physician profile
Michael Bianco
NPI 1275899288
$6,169.30
in general payments reported to CMS, 2019-2025
16 companies · $925 in 2025
The $925 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.00 · 2021: $441 · 2022: $1,026 · 2023: $2,578 · 2024: $1,100 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,023 · Travel and Lodging: $579 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,022.86 |
| Travel and Lodging | $579.16 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $3,531.40 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $1,733.86 | 2021-2025 | Watchman Access System, Watchman Flx, Versacross Access Solution |
| Medtronic, INC. | $152.86 | 2022 | |
| Novartis Pharmaceuticals Corporation | $123.65 | 2024-2025 | |
| Astellas Pharma US INC | $99.00 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.83 | 2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $94.24 | 2021-2023 | Farxiga |
| Pfizer INC. | $77.59 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $58.18 | 2023-2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $51.44 | 2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.11 | 2021-2025 | Jardiance |
| Penumbra, INC. | $27.99 | 2025 | Indigo System |
| Lantheus Medical Imaging, INC. | $23.99 | 2025 | |
| Abiomed | $22.40 | 2024 | Impella |
| Esperion Therapeutics, INC. | $21.50 | 2024 | Nexletol |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.26 | 2024 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bianco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.